Gene Expression and DNA Variation Analysis of Sacs to Identify the Pathophysiology of Indirect Inguinal Hernia

November 21, 2020 updated by: Oguz Kizilkaya, Trakya University

The aim of the project is to show that gene expression levels change in at least one of the GATA6 and T-box transcription factor 3 (TBX3) genes in indirect inguinal hernia sacs, thus revealing that this pathway causes an error in the sac closure pathway.

Indirect inguinal hernia is an important condition for human health as it is common in the community and can lead to life-threatening or permanent loss of function. In addition, since the treatment is performed surgically, the follow-up and treatment process of the patients should be managed carefully in terms of complications and costs. By explaining the mechanisms of the occurrence of this disease, important steps will be taken in terms of both human health and the development of science. Moreover, the data to be collected may open new horizons in the treatment of inguinal hernia.

20 inguinal hernia patients those consecutively applied to Trakya University Medical Faculty Department of Pediatric Surgery and 20 circumcision patients as control group will be included in the study.

Study Overview

Detailed Description

Indirect inguinal hernia is one of the pathologies that is widely researched in national and international studies because of its high prevalence in the community and its life-threatening or permanent loss of function. However, no point has been reached regarding the etiology of this disease and a consensus has been reached.

The investigators believe that the study will contribute to the explanation of the formation mechanisms of the mentioned disease. Considering the high prevalence of this disease and its potential for life-threatening, the investigators anticipate that the analysis of the relevant genes for the Turkish population will make significant contributions to the public health. In the literature, analysis of GATA6 SNPs in the Chinese population has subsequently associated certain polymorphisms with indirect inguinal hernia. It is also been stated that TBX3 gene pathologies may be associated with inguinal hernia.

However, there is no study in the literature about the patent processus vaginalis expression levels of these genes. There is no study on the SNP analysis of these genes in Turkish population. For these reasons, the first time the expression / SNP analysis of the specified genes in Turkish society will be carried out will make an additional contribution to scientific knowledge. As stated clearly in the studies, the implementation of medical treatment of indirect inguinal hernia may change the approach of the pediatric surgical community to indirect inguinal hernia. In order for medical treatment to be carried out, the formation pathways and genetic origins of the disease must be clearly revealed.

Investigating the relationship of GATA6 and TBX3 genes, which are known to be involved in connective tissue homeostasis, with the mechanisms of indirect inguinal hernia formation, will contribute to the studies in the literature and is important in terms of revealing whether the treatment of these diseases can be performed medically in the future.

The study aims to reveal that gene expression levels in indirect inguinal hernia sacs due to SNPs in at least one of the GATA6 and TBX3 genes, thus causing an error in the sac closure pathway. The hypothesis of the study; It is stated that the gene expression levels of at least one of GATA6 and TBX3 in the sacs of inguinal hernia patients are altered.

The primary goal of this study is; To determine the level of GATA6 and TBX3 gene expression in sacs obtained from indirect inguinal hernia patients. The secondary goal is to investigate SNPs in the leukocytes of these patients and to investigate whether the genetic elements in our hypothesis in these diseases are regulated by different genes acting as transcription factors.

Considering that indirect inguinal hernia poses significant health risks, especially in children, it is predicted that the results to be obtained may contribute to clarification of the etiology and non-invasive methods other than surgery.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Edirne, Turkey, 22030
        • Trakya University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 18 years (ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Probability Sample

Study Population

All patients applied to the Trakya University Hospital Pediatric Surgery Clinic that meet the inclusion criteria and whose legal representative gave consent to be enrolled included to the study.

Description

Inclusion Criteria:

  • to accept to participate the study
  • pediatric age
  • isolated indirect inguinal hernia patient with no additional systemic/congenital disease
  • patients requesting circumcision procedure with no additional systemic/congenital disease

Exclusion Criteria:

  • patients with any syndromic disease
  • patients with hypospadias
  • patients with undescended testes
  • patients with umbilical hernia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hernia
Patients planned to undergo routine indirect inguinal hernia repair procedure
mRNA expression and SNP analysis from samples
Peripheral blood sampling for SNP analysis
Control
Patients planned to undergo routine circumcision procedure
mRNA expression and SNP analysis from samples
Peripheral blood sampling for SNP analysis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gene expression and Single Nucleotide Polymorphism analysis
Time Frame: up to 3 months after completion of the study
Determining the varieties of messenger ribonucleic acid (mRNA) expression levels between groups and possible Single Nucleotide Polymorphisms (SNP)
up to 3 months after completion of the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Oguz Kizilkaya, Trakya University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 22, 2019

Primary Completion (ACTUAL)

November 1, 2020

Study Completion (ANTICIPATED)

November 20, 2020

Study Registration Dates

First Submitted

November 2, 2020

First Submitted That Met QC Criteria

November 11, 2020

First Posted (ACTUAL)

November 18, 2020

Study Record Updates

Last Update Posted (ACTUAL)

November 24, 2020

Last Update Submitted That Met QC Criteria

November 21, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to share the data at this time but it may be possible after completion of the publication process.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Genetic Predisposition to Disease

Clinical Trials on mRNA expression and SNP analysis

Subscribe